NOVACYT |
Market Closed -
Other stock markets
|
After market 03:59:45 pm | |||
| 0.83 EUR | +10.67% |
|
0.828 | -0.24% |
| 12:42pm | Novacyt: confident ahead of DHSC trial | CF |
| 12:36pm | Novacyt expects court to dismiss application by UK DHSC | AN |
| Sales 2021 | 95.78M 102M | Sales 2022 | 21.04M 22.42M | Capitalization | 76.79M 81.82M |
|---|---|---|---|---|---|
| Net income 2021 | -9M -9.59M | Net income 2022 | -25M -26.64M | EV / Sales 2021 | 1.67 x |
| Net cash position 2021 | 99.9M 106M | Net cash position 2022 | 86.29M 91.95M | EV / Sales 2022 | -0.45 x |
| P/E ratio 2021 |
-26.3
x | P/E ratio 2022 |
-2.99
x | Employees | 120 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 96.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novacyt
More news
| 1 day | +6.53% | ||
| 1 week | +34.74% | ||
| Current month | +54.55% | ||
| 1 month | +51.61% | ||
| 3 months | +31.85% | ||
| 6 months | +48.93% | ||
| Current year | +12.06% |
1 week
0.58
0.83
1 month
0.500.83
Current year
0.490.83
1 year
0.421.00
3 years
0.426.72
5 years
0.0613.96
10 years
0.0613.96
| Managers | Title | Age | Since |
|---|---|---|---|
James McCarthy
CEO | Chief Executive Officer | 58 | 21-01-04 |
Steven Gibson
DFI | Director of Finance/CFO | 41 | 17-03-31 |
Paul Oladimeji
CTO | Chief Tech/Sci/R&D Officer | - | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Heath
BRD | Director/Board Member | 76 | 15-06-28 |
John Brown
BRD | Director/Board Member | 69 | 23-09-07 |
Lyn Rees
BRD | Director/Board Member | 51 | 23-09-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.83 | +10.67% | 1 517 074 |
| 24-04-18 | 0.75 | +5.04% | 1,093,529 |
| 24-04-17 | 0.714 | +13.33% | 933,634 |
| 24-04-16 | 0.63 | -4.69% | 394,152 |
| 24-04-15 | 0.661 | +11.47% | 281,783 |
Real-time Euronext Paris, April 19, 2024 at 06:45 am EDT
More quotes
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
2024-04-24
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +12.06% | 56.42M | |
| -29.76% | 905M | |
| -19.45% | 130M | |
| -18.31% | 59.78M | |
| +2.98% | 58.78M | |
| -2.40% | 50.16M |
- Stock Market
- Equities
- ALNOV Stock
